Cargando…
Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection
Pulmonary exacerbations in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (Psae) infection are usually treated with dual intravenous antibiotics for 14 days, despite the lack of evidence for best practice. Intravenous antibiotics are commonly associated with various systemic adv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832909/ https://www.ncbi.nlm.nih.gov/pubmed/29560254 http://dx.doi.org/10.12688/f1000research.13298.2 |
_version_ | 1783303387375206400 |
---|---|
author | Mann, Nina Murray, Shirley Hoo, Zhe Hui Curley, Rachael Wildman, Martin J. |
author_facet | Mann, Nina Murray, Shirley Hoo, Zhe Hui Curley, Rachael Wildman, Martin J. |
author_sort | Mann, Nina |
collection | PubMed |
description | Pulmonary exacerbations in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (Psae) infection are usually treated with dual intravenous antibiotics for 14 days, despite the lack of evidence for best practice. Intravenous antibiotics are commonly associated with various systemic adverse effects, including renal failure and ototoxicity. Inhaled antibiotics are less likely to cause systematic adverse effects, yet can achieve airway concentrations well above conventional minimum inhibitory concentrations. Typically one inhaled antibiotic is used at a time, but dual inhaled antibiotics (i.e. concomitant use of two different inhaled antibiotics) may have synergistic effect and achieve better results in the treatment of exacerbations. We presented anecdotal evidence for the use of dual inhaled antibiotics as an acute treatment for exacerbations, in the form of a case report. A female in her early thirties with CF and chronic Psae infection improved her FEV (1) by 5% and 2% with two courses of dual inhaled antibiotics to treat exacerbations in 2016. In contrast, her FEV (1) changed by 2%, –2%, 0% and 2%, respectively, with four courses of dual intravenous antibiotics in 2016. Baseline FEV (1) was similar prior to all six courses of treatments. The greater FEV (1) improvements with dual inhaled antibiotics compared to dual intravenous antibiotics suggest the potential role of using dual inhaled antibiotics to treat exacerbations among adults with CF and chronic Psae infection, especially since a greater choice of inhaled anti-pseudomonal antibiotics is now available. A previous study in 1985 has looked at the concomitant administration of inhaled tobramycin and carbenicillin, by reconstituting antibiotics designed for parenteral administration. To our knowledge, this is the first literature to describe the concomitant use of two different antibiotics specifically developed for delivery via the inhaled route. |
format | Online Article Text |
id | pubmed-5832909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-58329092018-03-19 Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection Mann, Nina Murray, Shirley Hoo, Zhe Hui Curley, Rachael Wildman, Martin J. F1000Res Case Report Pulmonary exacerbations in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (Psae) infection are usually treated with dual intravenous antibiotics for 14 days, despite the lack of evidence for best practice. Intravenous antibiotics are commonly associated with various systemic adverse effects, including renal failure and ototoxicity. Inhaled antibiotics are less likely to cause systematic adverse effects, yet can achieve airway concentrations well above conventional minimum inhibitory concentrations. Typically one inhaled antibiotic is used at a time, but dual inhaled antibiotics (i.e. concomitant use of two different inhaled antibiotics) may have synergistic effect and achieve better results in the treatment of exacerbations. We presented anecdotal evidence for the use of dual inhaled antibiotics as an acute treatment for exacerbations, in the form of a case report. A female in her early thirties with CF and chronic Psae infection improved her FEV (1) by 5% and 2% with two courses of dual inhaled antibiotics to treat exacerbations in 2016. In contrast, her FEV (1) changed by 2%, –2%, 0% and 2%, respectively, with four courses of dual intravenous antibiotics in 2016. Baseline FEV (1) was similar prior to all six courses of treatments. The greater FEV (1) improvements with dual inhaled antibiotics compared to dual intravenous antibiotics suggest the potential role of using dual inhaled antibiotics to treat exacerbations among adults with CF and chronic Psae infection, especially since a greater choice of inhaled anti-pseudomonal antibiotics is now available. A previous study in 1985 has looked at the concomitant administration of inhaled tobramycin and carbenicillin, by reconstituting antibiotics designed for parenteral administration. To our knowledge, this is the first literature to describe the concomitant use of two different antibiotics specifically developed for delivery via the inhaled route. F1000 Research Limited 2018-02-28 /pmc/articles/PMC5832909/ /pubmed/29560254 http://dx.doi.org/10.12688/f1000research.13298.2 Text en Copyright: © 2018 Mann N et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Mann, Nina Murray, Shirley Hoo, Zhe Hui Curley, Rachael Wildman, Martin J. Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection |
title | Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic
Pseudomonas infection |
title_full | Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic
Pseudomonas infection |
title_fullStr | Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic
Pseudomonas infection |
title_full_unstemmed | Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic
Pseudomonas infection |
title_short | Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic
Pseudomonas infection |
title_sort | case report: dual nebulised antibiotics among adults with cystic fibrosis and chronic
pseudomonas infection |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832909/ https://www.ncbi.nlm.nih.gov/pubmed/29560254 http://dx.doi.org/10.12688/f1000research.13298.2 |
work_keys_str_mv | AT mannnina casereportdualnebulisedantibioticsamongadultswithcysticfibrosisandchronicpseudomonasinfection AT murrayshirley casereportdualnebulisedantibioticsamongadultswithcysticfibrosisandchronicpseudomonasinfection AT hoozhehui casereportdualnebulisedantibioticsamongadultswithcysticfibrosisandchronicpseudomonasinfection AT curleyrachael casereportdualnebulisedantibioticsamongadultswithcysticfibrosisandchronicpseudomonasinfection AT wildmanmartinj casereportdualnebulisedantibioticsamongadultswithcysticfibrosisandchronicpseudomonasinfection |